Immuron Ltd — Regulatory Filings 2011

Dec 15, 2011

==> picture [53 x 35] intentionally omitted <==

==> picture [55 x 35] intentionally omitted <==

==> picture [55 x 35] intentionally omitted <==

==> picture [4 x 35] intentionally omitted <==

IMMURON ENTERS INTO RESEARCH AGREEMENT WITH HARVARD MEDICAL SCHOOL

Melbourne, Australia, 16th December 2011 : A u stralian Bi o pharmac e utical com p any, Im m uron (ASX: I MC), manu f acturer of T r avelan® is p leased to a n nounce tha t it has ente r ed into a p a rtnership a g reement wi t h Dana‐Far b er Cancer I n stitute and Children’s H ospital Boston, whi c h is the pri m ary paedia t ric teachin g hospital of t he prestigi o us Harvard M edical Sch o ol.

The agreement i nvolves res e arch relati n g to specific preparatio n s of Immur o n’s antibod y ‐rich col o strum prod u ct, which f o rms the basis for its pro v en safe an d efficacious platform tec h nology. Un d er the agreement, these world ren o wn institutions will wo r k together t o test the effect of th e Immuron’s unique colo s trum prod u ct in people undergoin g radiation t h erapy and most importantly how i t can help r e duce the si d e‐effects o f cancer trea t ments. The agr e ement also extends to research usi n g Immuron’s technolog y and how it may treat newborn lun g inflammati o n.

The early data generated fr o m animal s t udies have b een encouraging to dat e and have p rovided imp e tus for this important research. Th e mechanis m of action h as a lot of m erit based o n other work done to d a te. Importa n tly, Immur o n retains the rights to any data gen e rated relating to its tec h nology.

Contact Joe Baini – Chie f Executive O fficer Rudi Michelson +61 3 8637 110 7 Monsoon C o mmunicati o ns +61 3 9620 3333 0411 4 0 2 737

About Immuron Limited

Im m uron is a bi o pharmaceu t ical compa n y focused o n oral immu n otherapy tr e atments using dairyderi v ed antibod y products for humans. I m muron is u n iquely positioned with a versatile te c hnology plat f orm capabl e of generati n g a wide range of prod u cts with a high safety pr o file. This high saf e ty profile m a kes it possi b le to compl e te pre-clini c al studies r e latively quic k ly and incr e ases the pro s pect that th e clinical de v elopment of Immuron’s p roducts will be expedit e d. Immuron’ s current pro d ucts and pr o duct candi d ates target infectious di s eases of th e gastrointe s tinal tract, c h ronic dis e ases such a s fatty liver (NASH), and the prevention of influe n za. Immur o n has one product in the m arket, Tra v elan, for pr e venting trav e llers’ diarrhoea. Immur o n’s main sc i entific allian c es are with Hadassah M edical Cen t er (Israel), t h e Universit y of Melbourne and Mon a sh University (Au s tralia).